XPARVLA
Market cap164mUSD
Dec 24, Last price
1.99EUR
1D
4.19%
1Q
-26.30%
Jan 2017
-35.60%
IPO
-79.52%
Name
Valneva SE
Chart & Performance
Profile
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 153,712 -57.46% | 361,303 3.80% | 348,085 215.52% | |||||||
Cost of revenue | 257,320 | 486,945 | 432,452 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (103,608) | (125,642) | (84,367) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 2,800 | 1,536 | 3,446 | |||||||
Tax Rate | ||||||||||
NOPAT | (106,408) | (127,178) | (87,813) | |||||||
Net income | (101,429) -29.21% | (143,279) 95.14% | (73,425) 14.03% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (240) | 189,837 | 166,823 | |||||||
BB yield | 0.07% | -25.85% | -6.16% | |||||||
Debt | ||||||||||
Debt current | 46,958 | 36,991 | 10,242 | |||||||
Long-term debt | 193,827 | 168,964 | 161,235 | |||||||
Deferred revenue | 4,741 | |||||||||
Other long-term liabilities | 11,094 | 8,070 | 167,348 | |||||||
Net debt | 114,705 | (83,475) | (177,289) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (202,744) | (245,343) | 76,901 | |||||||
CAPEX | (14,231) | (29,322) | (93,171) | |||||||
Cash from investing activities | (20,585) | (29,054) | (93,116) | |||||||
Cash from financing activities | 63,081 | 215,116 | 154,504 | |||||||
FCF | (134,431) | (107,385) | (183,490) | |||||||
Balance | ||||||||||
Cash | 126,080 | 289,430 | 346,642 | |||||||
Long term investments | 2,124 | |||||||||
Excess cash | 118,394 | 271,365 | 331,362 | |||||||
Stockholders' equity | (465,111) | (374,246) | (238,676) | |||||||
Invested Capital | 813,268 | 738,224 | 695,918 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 69,312 | 115,474 | 97,619 | |||||||
Price | 5.18 -18.48% | 6.36 -77.09% | 27.76 258.13% | |||||||
Market cap | 359,349 -51.07% | 734,414 -72.89% | 2,709,424 285.21% | |||||||
EV | 474,054 | 650,939 | 2,532,135 | |||||||
EBITDA | (86,024) | (104,606) | (70,086) | |||||||
EV/EBITDA | ||||||||||
Interest | 23,325 | 19,054 | 16,963 | |||||||
Interest/NOPBT |